ArticleJACC. Case reports2025
Emergency Heart Transplantation for Recurrent Infective Endocarditis With Irreparable Damage: A Case Beyond Conventional Surgery.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfective endocarditis (IE) with irreversible structural damage has high mortality despite conventional surgery. Heart transplantation (HTx) remains underused in active IE owing to guideline limitations and historical contraindications. CASE SUMMARY: A 61-year-old man with recurrent prosthetic valve IE (aortic/tricuspid vegetations, perivalvular abscesses, and coronary embolism) developed cardiogenic shock. Multidisciplinary evaluation deemed conventional repair futile. Emergency HTx achieved survival, with no infection recurrence at 4-month follow-up under prolonged antibiotics and immunosuppression. DISCUSSION: Whereas guidelines reserve HTx for healed IE, recent evidence supports its role in active infection with controlled bacteremia. This case highlights feasibility of HTx in anatomically destructive IE, urging guideline updates to prioritize transplantation over high-risk valve-centric approaches. TAKE-HOME MESSAGES: HTx may represent a last-resort option for end-stage IE with irreparable damage, even in active infection. This exceptional case required both multidisciplinary consensus and timely organ availability. Multidisciplinary protocols integrating prolonged antibiotics and tailored immunosuppression are critical for success.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.